6 курс / Кардиология / Коронарное_стентирование_и_стенты

Стент имеет высокую радиальную устойчивость, обладает хорошей гибкостью, четко повторяет контур сосуда после имплантации и имеет превосходную память формы.

Стент Amaranth FORTITUDE? так же прочен, как и любой металлический стент во время доставки и имплантации в область стеноза, однако после имплантации со временем, начиная с 3 мес, постепенно начинает разрушаться и постепенно исчезает, а полная биорезорбция заканчивается примерно через 24-36 мес после имплантации (рис. 141).

В первое исследование вошли 13 пациентов с изолированным поражением венечных артерий. Результаты исследования показали, что каркас стента Amaranth FORTITUDE? сохраняет свою механическую

целостность сразу после имплантации. Отмечалась поздняя потеря просвета, сравнимая с наблюдаемой при использовании голометалли-ческих стентов

[209].

Рис. 141. Стент Amaranth FORTITUDE

Медицинские книги

@medknigi

СПИСОК ЛИТЕРАТУРЫ

1. Serruys P.W., Onuma Y., Garg S., Vranckx P., DeBruyne B., Morice M.C., Colombo A., Macaya C., Richardt G., Fajadet J., Hamm C., Schuijer M., Rade-maker T., Wittelbols K., Stoll H.P. ARTS IIInvestigators. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the siroli-mus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions // J. Am. Coll Cardiol. 2012. Vol. 55. P. 1093-1101.

1a. Sianos G., Morel M.A., Kappetein A.P., et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005. Vol. 1. P 219-27.

2. Mohr F.W., Morice M.C., Kappetein A.P., Feldman T.E., Stahle E., Colombo A., Mack M.J., Holmes D.R. jr, Morel M.A., Van Dyck N., Houle V.M., Dawkins K.D., Serruys P.W. Coronary artery bypass surgery versus percutaneous coronary intervention with three-vessel disease and left main coronary disease: 5-year follow-up of the randomized, clinical SYNTAX trial // Lancet. 2013.

Vol. 381. P. 629-638.

3.Sigwart U., Puel J., Mirkowitch V. et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty // N. Engl. J. Med. 1987. Vol. 316. P. 701-706.

4.Gruntzig A.R., Senning A., Siegenthaler W.E. Non-operative dilatation of coronary artery stenosis: percutaneous transluminal coronary angioplasty // N. Engl. J. Med. 1979. Vol. 301. P. 61-68.

5.Rousseau H., Puel J., Joffre F. et al. Self expanding endovascular prosthesis: an experimental study. Radiology. 1987. Vol. 164. P. 709-714.

6.Coronary and Endovascular stents. Interventional Cardiology Clinics. Editor-In- Chief M.J. Price, Editor S.A. Parikh, Elsevier Inc. USA, July, 2016. Vol. 5, N. 3.

P. 273-275.

7.Dotter C.T., Buschmann R.W., McKinney M.K. et al. Transluminal expandable nitinol coil stent grafting: preliminary report // Radiology. 1983. Vol. 147.

P. 259-260.

8. Cragg А.A., Lund А.G., Rysрavy А.J. et al. Nonsurgical placement of arterialendoprosthesis: a new technique using nitinol wire // Radiology. 1983. Vol. 147.

P. 259-260.

Медицинские книги

@medknigi

9.Иоселиани Д.Г., Шахнович А., Филатов А.А., Левандовская А.Б., Танхиле-вич Б.М. Эндоваскулярное протезирование венечной артерии сердца при остром инфаркте миокарда // Кардиология. 1992. № 11-12, т. 32. С. 28-33.

10.Fischman D.L., Leon M., Baim D.S. et al. A randomized comparison of coronary stent placement and ballon angioplasty in the treatment of coronary artery disease // N. Engl. J. Med. 1994. Vol. 27. P. 255-261.

11.Serruys P.W., de Jaegere P., Kiemeneij F. et al. For the BENESTENT Study Group. A comparison of ballon-expandable stent implantation with ballon Angioplasty in patients with coronary artery disease // N. Engl. J. Med. 1994. Vol.

331.P. 489-495.

12.Rogers C., Parikh S., Seifert P., Edelman E.R. Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair // Circulation. 1996 Dec 1. Vol. 94(11). P. 2909-2914.

13.Kocum T., Yurtdas M., Ozcan T., Akcay B., Erol T., Camsari A., Doven O. Direct stenting versus predilatation and stenting technique when using paclitaxeleluting stents // Int. Heart J. 2008 Sep. Vol. 49(5). P. 545-552.

14.Brueck M., Scheinert D., Wortmann A., Bremer J., von Korn H., Klingham-mer L., Kramer W., Flachskampf F.A., Daniel W.G., Ludwig J. Direct coronary stenting versus predilatation followed by stent placement // Am. J. Cardiol. 2002,

Dec 1. Vol. 90(11). P. 1187-1192.

15. Ormiston J.A., Mahmud E., Turco M.A., Popma J.J., Weissman N., Cannon L.A., Mann T., Lucca M.J., Lim S.T., Hall J.J., McClean D., Dobies D., Mandinov L., Baim D.S. Direct stenting with the TAXUS Liberté drug-eluting stent: results from the Taxus Atlas Direct Stent Study // JACC Cardiovasc. Interv.

2008 Apr. Vol. 1 (2). P. 150-160.

16.Piscione F., Piccolo R., Cassese S., Galasso G., D'Andrea C., De Rosa R., Chiariello M. Is direct stenting superior to stenting with predilation in patients treated with percutaneous coronary intervention? Results from a meta-analysis of

24randomised controlled trials // Heart. 2010 Apr. Vol. 96(8). P. 588-594.

17.Barbato E., Marco J., Wijns W. Direct stenting // Eur. Heart J. 2003 Mar.

Vol. 24 (5). P. 394-403.

18. Figulla H.R., Mudra H., Reifart N., Werner G.S. Direct coronary stenting without predilatation: a new therapeutic approach with a special balloon catheter design

//

Cathet. Cardiovasc. Diagn. 1998 Mar. Vol. 43(3). P. 245-252.

Медицинские книги

@medknigi

19. Loubeyre C., Shgaier M, Angioi M. stenting without predilation (direct stenting) prevents myonecrosis in patients with non-ST elevation acute coronary syndrome and glycoprotein IIb/IIIa inhibitor treatment // Am. J. Cardiol. 2002. Vol. 90

(suppl 6A). P. 164H.

20.Shengxian Tu, Liang Xu, Jurgen Ligthart, Bo Xu, Karen Witberg, Zhongwei Sun, Gerhard Koning, Johan H.C. Reiber and Evelyn Regar. In vivo comparison of arterial lumen dimensions assessed by co-registered three-dimensional (3D) quantitative coronary angiography, intravascular ultrasound and optical coherence tomography // Int. J. Cardiovasc. Imaging. 2012 Aug. Vol. 28(6). P. 1315-1327.

21.Kubo T., Akasaka T., Shite J., Suzuki T., Uemura S., Yu B., Kozuma K., Kitaba-ta H., Shinke T., Habara M., Saito Y., Hou J., Suzuki N., Zhang S. OCT compared with IVUS in a coronary lesion assessment: the OPUS-CLASS study // JACC Cardiovasc. Imaging. 2013 Oct. Vol. 6(10). P. 1095-1104.

22.Tu S., Xu L., Ligthart J., Xu B., Witberg K., Sun Z., Koning G., Reiber J.H., Re-gar E. In vivo comparison of arterial lumen dimensions assessed by co-registered three-dimensional (3D) quantitative coronary angiography, intravascular ultrasound and optical coherence tomography // Int. J. Cardiovasc. Imaging. 2012 Aug.

Vol. 28(6). P. 1315-1327.

23.Palmerini T., Alessi L., Rizzo N., Dangas G. Percutaneous revascularization of left main: role of imaging, techniques, and adjunct pharmacology // Catheter. Car-diovasc. Interv. 2012 May 1. Vol. 79(6). P. 990-999.

24.Park S.J., Kim Y.H., Park D.W., Lee S.W., Kim W.J., Suh J., Yun S.C., Lee C.W., Hong M.K., Lee J.H., Park S.W. MAIN-COMPARE Investigators. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis // Circ. Cardiovasc. Interv. 2009 Jun. Vol. 2 (3).

P. 167-177.

25. Hong S.J., Kim B.K., Shin D.H., Nam C.M., Kim J.S., Ko Y.G., Choi D., Kang T.S., Kang W.C., Her A.Y., Kim Y.H., Hur S.H., Hong B.K., Kwon H.,

Jang Y., Hong M.K. IVUS-XPL Investigators. Effect of Intravascular UltrasoundGuided vs Angiography-Guided Everolimus-Eluting Stent Implantation: The IVUSXPL Randomized Clinical Trial // JAMA. 2015 Nov 24. Vol. 314(20).

P. 2155-2163.

Медицинские книги

@medknigi

26. Kim J.S., Kang T.S., Mintz G.S., Park B.E., Shin D.H., Kim B.K., Ko Y.G., Choi D., Jang Y., Hong M.K. Randomized comparison of clinical outcomes between intravascular ultrasound and angiography-guided drug-eluting stent implantation for long coronary artery stenoses // JACC Cardiovasc. Interv. 2013 Apr.

Vol. 6(4). P. 369-376.

27.Tian N.L., Gami S.K., Ye F., Zhang J.J., Liu Z.Z., Lin S., Ge Z., Shan S.J., You W., Chen L., Zhang Y.J., Mintz G., Chen S.L. Angiographic and clinical comparisons of intravascular ultrasound-versus angiography-guided drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study // EuroIntervention. 2015 Apr. Vol. 10(12). P. 1409-1417.

28.Kim B.K., Shin D.H., Hong M.K., Park H.S., Rha S.W., Mintz G.S., Kim J.S., Kim J.S., Lee S.J., Kim H.Y., Hong B.K., Kang W.C., Choi J.H., Jang Y. CTO-IVUS Study Investigators. Clinical Impact of Intravascular Ultrasound-Guided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus Bioli-mus-Eluting Stent Implantation: Randomized Study // Circ. Cardiovasc. Interv.

2015 Jul. Vol. 8 (7). P. e002592.

29. Takahashi M., Miyazaki S., Myojo M., Sawaki D., Iwata H., Kiyosue A., Higashikuni Y., Tanaka T, Fujita D., Ando J., Fujita H., Hirata Y., Komuro I. Impact of the distance from the stent edge to the residual plaque on edge restenosis following everolimus-eluting stent implantation // PLoS One. 2015 Mar 16. Vol. 10 (3).

P. e0121079.

30.Pache J., Kastrati A., Mehilli J., Schühlen H., Dotzer F., Hausleiter J., Fleckenstein M., Neumann F.J., Sattelberger U., Schmitt C., Müller M., Dirschinger J., Schömig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial // J. Am. Coll Cardiol. 2003 Apr 16. Vol. 41(8). P. 1283-1288.

31.Foin N., Lee R.D., Torii R., Guitierrez-Chico J.L., Mattesini A., Nijjer S., Sen S., Petraco R., Davies J.E., DiMario C., Joner M., Virmani R., Wong P. Impact

of stent strut design in metallic stents and biodegradable scaffolds // Int. J. Cardiol. 2014 Dec 20. Vol. 177(3). P. 800-808.

32. Joner M., Nakazawa G., Finn A.V., Quee S.C., Coleman L., Acampado E., Wilson P.S., Skorija K., Cheng Q., Xu X., Gold H.K., Kolodgie F.D., Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents // J. Am. Coll Cardiol. 2008 Jul 29. Vol. 52(5). P. 333-342.

Медицинские книги

@medknigi

33.Windecker S., Remondino A., Eberli F.R., Jüni P., Räber L., Wenaweser P., Togni M., Billinger M., Tüller D., Seiler C., Roffi M., Corti R., Sütsch G., Maier W., Lüscher T., Hess O.M., Egger M., Meier B. Sirolimus-eluting and paclitax-el-eluting stents for coronary revascularization // N. Engl. J. Med. 2005, Aug 18. Vol. 353 (7). P. 653-662.

34.Morice M.C., Colombo A., Meier B., Serruys P, Tamburino C., Guagliumi G., Sousa E., Stoll H.P. REALITY Trial Investigators. Sirolimusvs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial // JAMA. 2006 Feb 22. Vol. 295(8). P. 895-904.

35.Stone G.W., Midei M., Newman W., Sanz M., Hermiller J.B., Williams J., Far-hat N., Caputo R., Xenopoulos N., Applegate R., Gordon P., White R.M., Sud-hir K., Cutlip D.E., Petersen J.L. SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial // Circulation. 2009 Feb 10. Vol. 119(5). P. 680-686.

36.Stone G.W., Midei M., Newman W., Sanz M., Hermiller J.B., Williams J., Far-hat N., Mahaffey K.W., Cutlip D.E., Fitzgerald P.J., Sood P., Su X., Lansky A.J. SPIRIT IIIInvestigators. Comparison of an everolimus-eluting stent and a pac-litaxel- eluting stent in patients with coronary artery disease: a randomized trial //

JAMA. 2008 Apr 23. Vol. 299(16). P. 1903-1913.

37.Bangalore S., Kumar S., Fusaro M., Amoroso N., Kirtane A.J., Byrne R.A., Williams D.O., Slater J., Cutlip D.E., Feit F. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials // British Medical J. 2012 Aug 10. Vol. 345. P. e5170.

38.Lee K., Ann T.H., Suh S.Y., Kang W.C., Han S.H., Shin E.K. Six types ofdrug-elu- ting stents shows the similar clinical outcomes for the treatment of ST-segment elevation myocardial infarction // Eur. Heart J. 2013 Aug. Vol. 34 (suppl. 1). P.

3068.

39.Palmerini T., Benedetto U., Biondi-Zoccai G., Della Riva D., Bacchi-Reggiani L., Smits P.C., Vlachojannis G.J., Jensen L.O., Christiansen E.H., Berencsi K., Val-gimigli M., Orlandi C., Petrou M., Rapezzi C., Stone G.W. Long-Term Safety of DrugEluting andBare-Metal Stents: Evidence From a Comprehensive Network MetaAnalysis // J. Am. Coll Cardiol. 2015 Jun 16. Vol. 65(23). P. 2496-2507.

40.Kandzari D.E., Leon M.B., Popma J.J., Fitzgerald P.J., O'Shaughnessy C.,

Ball M.W., Turco M., Applegate R.J., Gurbel P.A., Midei M.G., Badre S.S., Mauri L., Thompson K.P., LeNarz L.A., Kuntz R.E. ENDEAVOR III Investi-

Медицинские книги

@medknigi

gators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial // J. Am. Coll

Cardiol. 2006 Dec 19. Vol. 48(12). P. 2440-2447.

41.vonBirgelen C., Basalus M.W., Tandjung K., vanHouwelingen K.G., Stoel M.G.,

Louwerenburg J.H., Linssen G.C., Saïd S.A., Kleijne M.A., Sen H., Löwik M.M., vanderPalen J., Verhorst P.M., deMan F.H. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial // J. Am. Coll Cardiol. 2012 Apr 10. Vol. 59(15). P. 1350-1361.

42.Stefanini G.G., Kalesan B., Serruys P.W., Heg D., Buszman P., Linke A., Ischinger T., Klauss V., Eberli F., Wijns W., Morice M.C., DiMario C., Corti R., Antoni D., Sohn

H.Y., Eerdmans P., vanEs G.A., Meier B, Windecker S., Jüni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial // Lancet. 2011 Dec 3. Vol. 378(9807). P. 1940-1948.

43.Barlis P., Regar E., Serruys P.W., Dimopoulos K., van der Giessen W.J., van

Geuns R.J., Ferrante G., Wandel S., Windecker S., van Es G.A., Eerdmans P., Jüni P., di Mario C. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study //

Eur. Heart J. 2010 Jan. Vol. 31(2). P. 165-176.

44. Serruys P.W., Farooq V., Kalesan B., de Vries T., Buszman P., Linke A., Ischinger T., Klauss V., Eberli F., Wijns W., Morice M.C., Di Mario C., Corti R., Antoni D., Sohn H.Y., Eerdmans P., Rademaker-Havinga T., van Es G.A., Meier B., Jüni P., Windecker

S. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymerbased sirolimus-eluting stents in patients with coronary artery disease: final 5- year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial // JACC Cardiovasc.

Interv. 2013 Aug. Vol. 6(8). P. 777-789.

45. Georgios J. Vlachojannis, Pieter C. Smits, Sjoerd H. Hofma, Mario Togni,

Nicolas Vazquez, Mariano Valdés, Vassilis Voudris, Ton Slagboom, Jean-Jaques Goy, Peter-den Heijerand Martinvander Ent. Biodegradable Polymer BiolimusEluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease. Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable

Медицинские книги

@medknigi

Polymer Everolimus-Elu-ting Stent) // JACC Cardiovasc. Interv. 2017 Jun 26. Vol. 10 (12). P. 1215-1221.

46.Byrne R.A., Kastrati A., Massberg S., Wieczorek A., Laugwitz K.L., Hadamitz-ky

M., Schulz S., Pache J., Fusaro M., Hausleiter J., Schömig A., Mehilli J. ISAR-TEST 4 Investigators. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus-versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial // J. Am. Coll Cardiol. 2011. Sep 20. Vol. 58(13). P. 1325-1331.

47.Raungaard B., Christiansen E.H., Bøtker H.E., Hansen H.S., Ravkilde J., Thue-sen

L., Aarøe J., Villadsen A.B., Terkelsen C.J., Krusell L.R., Maeng M., Kristen-sen S.D., Veien K.T., Hansen K.N., Junker A., Madsen M., Andersen S.L., Jensen S.E., Jensen L.O. SORTOUT VI Investigators. Comparison of Durable-Polymer ZotarolimusEluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 74.3-Year Clinical Outcomes in

the Randomized SORT OUT VI Trial // JACC Cardiovasc. Interv. 2017 Feb 13. Vol. 10(3). P. 255-264.

48.deWaha A., Stefanini G.G., King L.A., Byrne R.A., Serruys P.W., Kufner S., Meier

B., Jüni P., Kastrati A., Windecker S. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials // Int. J. Cardiol. 2013, Oct 15. Vol. 168(6). P. 5162-5166.

49.Reisman M. Guide to rotational atherectomy. Royal Oak, MI: Physisians' Press, 1997.

50.Sharma S.K., Kini A., Mehran R. et al. Randomized trials of Rotational Atherectomy Versus Ballon Angioplasty for Diffuse in-Stent Restenosis (ROSTER) // Am. Heart. J. 2004. Vol. 147. P. 16-22.

51.vom Dahl J., Dietz U., Haager P.K. et al. Rotational Atherectomy does not reduce reccurent in-stent restenosis: resuls of the Angioplasty versus Rotational Atherectomy for Treatment of Diffuse In-stent Restenosis Trial (ARTIST) // Circulation. 2002. Vol. 105. P. 583-588.

52.Ellis S.G., Holmes D.R.-junior. Strategic Approaches in Coronary Intervention. Lippincott: Williams&Wilkins, 2006. P. 248-253.

53.Adelman A.G., Cohen E.A., Kimball B.P. et al. A comparison of directional atherectomy with ballon angioplasty for lesions of the anterior descending coronary artery // N. Engl. J. Med. 1993. Vol. 329. P. 228-233.

Медицинские книги

@medknigi

54.Topol E.J., Leya F., Pinkerton C.A. et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group // N. Engl. J. Med. 1993. Vol. 329. P. 221-227.

55.Baim D.S., Cutlip D.E., Sharma S.K. et al. Final results of the Ballon versus Optimal Atherectomy Trials (BOAT) // Circulation. 1998. Vol. 97. P. 322-331.

56.Suzuki T., Hosokawa H., Katoh O. et al. Effects of adjunctive ballon angioplasty after intravascular ultrasound-guided optimal directional coronary atherectomy: the result of adjunctive Ballon Angioplasty after Coronary Atherectomy Study (ABACAS) // J. Am. Coll Cardiol. 1999. Vol. 34. P. 1028-1035.

57.Sousa J.E., Cost M.A., Abizaid A.C., Rensing B.J., Abizaid A.S., Tanajura L.F., Kozuma K., Van Langenhove G., Falotico R., Jaeger J., Popma J.J., Serruys P.W. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up // Circulation. 2001. Vol. 104. P. 2007-2011.

58.Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R. RAVEL

Study Group. A randomized comparison of a Sirolimus-eluting stent with a standard stent for coronary revascularization // New Engl. J. Med. 2002. Vol. 346.

P. 1773-1780.

59.Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vrancfx P., NcFadden, Lansky A., Hamon M., Krucoff M.W., Serruys P.W. Academic Research Consortium. Clinlcal end points in coronary stent trials: a case for standardized definitions // Circulation. 2007. Vol. 115. P. 2344-2351.

60.Gaspard P. The history of coronary angioplasty. Europa Digital & Publishing, 2017. P. 159-160.

61.Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., Cutlip D.E., Fahy M., Po-cock S.J., Mehran R., Leon M.B. Safety and efficacy of sirolimusand paclitaxel-eluting coronary stents // N. Engl. J. Med. 2007. Vol. 356. P. 998-1008.

62.Scheller B., Hehrlein C., Bocksch W., Rutsch W., Haghi D., Dietz U., Bohm M., Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated ballon

catheter // N. Engl. J. Med. 2006. Vol. 355. P. 2113-2124.

63. Rittiger H., Brachmann J., Sinha A.M., Waliszewski M., Ohlow M., Brugger A., Thiele H., Birkemeyer R., Kurowski V., Breithardt O.A., Schmidt M., Zimmer-mann

Медицинские книги

@medknigi

S., Lonke S., von Cranach M., Nguyen T.V., Daniel W.G., Wohrle J. A randomized, multizenter, single-blinded trial comparing paclitaxel-coated ballon angioplasty with plain ballon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study // J. Am. Coll Cardiol. 2012. Vol. 59. P. 1377-1382.

64. Taniwaki M., Stefanini G.G. Silber S. Richardt G., Vranckx P., Serruys P.W., Buzman P.E. Kelbaek H., Windecker S. RESOLUTE All-Comers Investigators. 4- years clinical outcomes and predictors of repear revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-comers trial (A Randomized comparison a Zotarolimus-Eluting Stent for Percutaneous Coronary Intervention) // J. Am. Coll Cardiol. 2014. Vol. 63.

P. 1617-1625.

65.Stefanini G.G., Kalesan B., Serruys P.W., Heg D., Buszman P., Linke A., Ischinger T., Klauss V., Eberli F., Wijns W., Morice M.C., Di Marco C., Corti R., An-toni D., Sohn H.Y., Eerdmans P., van Es G.A., Meier B., Windecker S., Juni P. Long-term Clinical outcomes of biodegradable polimer biolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow up of a randomized noninferiority trial // Lancet. 2011. Vol. 378. P. 1940-1948.

66.Raber L., Kelbaek H., Ostojic M., Baumbach A., Heg D., Tuller D., von Birge-len C., Roffi M., Moshcovitis A., Khattab A.A., Wenaweser P., Bonvini R., Pe-drazzini G., Kornowski R., Weber K., Trelle S., Luscher T.F., Taniwaki M., Matter C.M., Meier B., Juni P., Windecker S. COMFORTABLE AMI Trial Investigators. Effect of biolimuseluting stents with biodegradanle polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial // JAMA. 2012. Vol. 308. P. 777-787.

67.Danzi G.B., Chevalier B., Urban P., Fath-Ordoubadi F., Carrie D., Wiemer M., Serr A., Wijns W., Kala P., Stabile A., Ruigomez H.G., Sagic D., Laanmets P., Strupp G., West N., Paunovic D. NOBORI 2 Investigators. Clinical performance of a drugeluting stent with a biodegradable polumer in an uselected ptient population: the NOBORI 2 study // Eurointervention. 2012. Vol. 8. P. 109-116.

68.Smits P.C., Hofma S., Togni M., Vazquez N., Valdes M., Voudris V., Slagboom T., Goy J.J., Vuillomenet A., Serra A., Nouche R.T., den Heijer P., van der Ent M. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomized, controlled, non-inferior trial // Lancet. 2013. Vol. 381. P. 651-660.

69.Urban P., Meredith I.T., Abizaid A., Pocock S.J., Carrie D., Naber C., Li-piecki J., Richardt G., Ingiuez A., Brunel P., Valdes-Chavarri M., Garot P., Tal-war S., Berland J., Abdellaoui M., Eberli F., Oldroyd K., Zambahari R., Greg-son J.,.Greene S., Stol H.P., Morice M.C. LEADERS FREE Investigators. Polymer-free Drug Coated Coronary Stents in Patients at High Bleeding Risk //

Медицинские книги

@medknigi